Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

RVV.CN : 0.0100 (unch)
RVVTF : 0.0063 (+3.28%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0100 (unch)
RVVTF : 0.0063 (+3.28%)
Stocks in play: Revive Therapeutics Ltd

Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0063 (+3.28%)
RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0063 (+3.28%)
RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0063 (+3.28%)
RVV.CN : 0.0100 (unch)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0063 (+3.28%)
RVV.CN : 0.0100 (unch)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.0063 (+3.28%)
RVV.CN : 0.0100 (unch)

Barchart Exclusives

Elon Musk Says Building a Startup Isn't For Everyone, You've Got to 'Have a High Pain Threshold'
In a revealing commentary on the trials of entrepreneurship, Tesla (TSLA) and SpaceX CEO Elon Musk shared a stark reminder: “Starting a business is not for everyone. Starting a business—I’d say, number one is have a high pain threshold.” Musk’s candid advice offers insight into the demanding realities of launching... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar